Phaxiam Therapeutics SA (WKN A3EJH8, ISIN FR001400K4B1) - Ad-hocs

15.04.24 - GlobeNewswire

PHAXIAM Therapeutics announces enrolment of the first patient in the phase 1 study for the treatment of endocarditis infections caused by Staphylococcus aureus

The study plans for the enrolment of 12 patients in 5 French clinical centers First study results expected in Q3 2024 This study will enable an evaluation of the intravenous ...

05.04.24 - GlobeNewswire

PHAXIAM Therapeutics announces filing of its 2023 Universal Registration Document (URD)

11.03.24 - GlobeNewswire

PHAXIAM Therapeutics announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market

Lyon (France) and Cambridge (MA, US), March 11, 2024, at 07:00am CET – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), a biopharmaceutical company developing innovative ...

20.02.24 - GlobeNewswire

PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market

14.11.23 - GlobeNewswire

PHAXIAM Provides Business and Financial Update for the Third Quarter of 2023

Conference call and webcast (English) on Wednesday, November 15, 2023

24.10.23 - GlobeNewswire

PHAXIAM Therapeutics obtains authorizations to launch its phase 1 study in endocarditis infections caused by Staphylococcus aureus

23.10.23 - GlobeNewswire

TP ICAP Midcap initiates coverage of PHAXIAM Therapeutics with a “Buy” recommendation

Lyon (France) et Cambridge (MA, US), October 23, 2023, at 10:05 pm CEST – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), a biopharmaceutical company developing ...

19.09.23 - GlobeNewswire

PHAXIAM Therapeutics extends its phage portfolio to Klebsiella pneumoniae, a new resistant and aggressive bacterial target

PHAXIAM Therapeutics extends its phage portfolio to Klebsiella pneumoniae , a new resistant and aggressive bacterial target

18.09.23 - GlobeNewswire

PHAXIAM Therapeutics announces the completion of its reverse share split

PRESS RELEASE

05.09.23 - GlobeNewswire

PHAXIAM Therapeutics publishes its cash position and new financial calendar, and announces its participation at upcoming investor conferences

P HAXIAM Therapeutics publishes its cash position and new financial calendar, and announces its participation at upcoming investor conferences

08.08.23 - GlobeNewswire

Monthly information related to total number of voting rights and shares composing the share capital _July 31, 2023

Monthly information related to total number of voting rights and shares composing the share capital _ Ju ly 31 , 202 3 . Article 223-16 of general regulation of French Autorité des ...

27.07.23 - GlobeNewswire

PHAXIAM Therapeutics announces a reverse share split of its shares

PRESS RELEASE

28.06.23 - GlobeNewswire

Phaxiam Therapeutics announces its new mnemonic code on Euronext and Nasdaq: PHXM

P haxiam Therapeutics announces its new mnemonic code on Euronext and Nasdaq: PHXM

26.06.23 - GlobeNewswire

ERYTECH and PHERECYDES announce merger and name change to PHAXIAM Therapeutics

23.06.23 - GlobeNewswire

ERYTECH announces the approval of the merger with Pherecydes and reports the results of the Combined Shareholder’s Meeting held on June 23, 2023

ERYTECH announces the approval of the merger with Pherecydes and reports the results of the Combined Shareholder’s Meeting held on June 2 3 , 202 3 All resolutions voted ...

20.06.23 - GlobeNewswire

ERYTECH announces that Akkadian is continuing its attempt at destabilization with the filing of a new lawsuit

14.06.23 - GlobeNewswire

ERYTECH announces that the Commercial Court has rejected Akkadian's request to postpone the vote on the merger with Pherecydes Pharma

12.06.23 - GlobeNewswire

ERYTECH Responds to Akkadian’s Disinformation

05.06.23 - GlobeNewswire

ERYTECH announces that Akkadian has initiated proceedings to postpone the vote on the merger with Pherecydes

24.05.23 - GlobeNewswire

ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 23, 2023

ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 2 3 , 20 2 3

Deine verpassten Browser Pushes der letzten 24 Stunden:

Phaxiam Therapeutics SA News

Ad-hocs

Newssuche

Videos

Schnelle Produktionsaufnahme